Physician profile
Jason E Hendrix
NPI 1407037237
$16,121.05
in general payments reported to CMS, 2019-2025
48 companies · $2,752 in 2025
The $2,752 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $954 · 2021: $1,948 · 2022: $2,686 · 2023: $2,942 · 2024: $3,186 · 2025: $2,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,696 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,696.14 |
| Education | $183.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,786.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,538.79 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,133.62 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $853.08 | 2019-2025 | |
| Genzyme Corporation | $803.75 | 2019-2025 | |
| Janssen Biotech, INC. | $781.10 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $765.30 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $703.76 | 2019-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $611.40 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $542.62 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Lilly USA, LLC | $529.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $528.11 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $396.17 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $330.84 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Pfizer INC. | $310.56 | 2020-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $296.89 | 2022-2024 | Vtama |
| Almirall LLC | $184.28 | 2019-2025 | Klisyri, Seysara |
| Genentech USA, INC. | $180.41 | 2019-2025 | Xolair |
| Kyowa Kirin, INC. | $160.12 | 2023-2024 | Poteligeo |
| Journey Medical Corporation | $127.59 | 2019-2023 | |
| Organogenesis INC. | $126.35 | 2021-2025 | Novachor, Puraply Wound Matrix |
| Mission Pharmacal Company | $113.40 | 2019-2022 | |
| Epi Health, LLC | $105.15 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $103.11 | 2020 | |
| Mayne Pharma Commercial LLC | $100.07 | 2019-2020 | |
| Organon LLC | $96.98 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Celgene Corporation | $76.03 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $71.95 | 2019-2021 | |
| Strata Skin Sciences, INC. | $64.84 | 2021-2025 | Xtrac |
| Fresenius Kabi USA, LLC | $62.44 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Verrica Pharmaceuticals INC. | $59.37 | 2023-2024 | Ycanth |
| Botanix Sb INC | $54.00 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $52.41 | 2023-2025 | Zoryve |
| Biofrontera INC. | $49.14 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ani Pharmaceuticals, INC. | $40.46 | 2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $36.91 | 2025 | Nuzyra |
| Mylan Pharmaceuticals INC. | $36.70 | 2019 | |
| Revance Therapeutics, INC. | $34.22 | 2024 | Daxxify |
| Dermira, INC. | $34.12 | 2019-2020 | |
| Encore Dermatology INC. | $32.87 | 2019 | |
| Blueprint Medicines Corporation | $31.15 | 2025 | Ayvakit |
| Dusa Pharmaceuticals, INC. | $27.56 | 2019 | |
| Aclaris Therapeutics, INC. | $23.43 | 2019 | |
| Genentech, INC. | $15.70 | 2023 | Erivedge |
| Merck Sharp & Dohme LLC | $14.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.84 | 2024 | Spevigo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.